Induction of humoral and cellular immune responses against the HIV-1 envelope protein using -retroviral virus-like particles

Virology Journal

Volumn 8, Issue , 2011, Pages

  Kirkegaard, Tea ^a   Wheatley, Adam ^d   Melchjorsen, Jesper ^a   Bahrami, Shervin ^b   Pedersen, Finn S ^c   Center, Robert J ^d   Purcell, Damian Fj ^d   Ostergaard, Lars ^a   Duch, Mogens ^c   Tolstrup, Martin ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b INCUBA Science Park ^*  (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

retroviruses; HIV 1 envelope protein; immunity; Virus like particles

Indexed keywords

GLYCOPROTEIN GP 160; IMMUNOGLOBULIN G2A; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; VIROSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; GAMMA RETROVIRAL LIKE PARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; MICROSOME; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; BLOOD; FEMALE; IMMUNOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ANIMALS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV-1; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VIROSOMES;

EID: 79960881788     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-381     Document Type: Article

References (22)

1. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Johnson PR, Schnepp BC, Zhang J, et al. Nat Med 2009 15 901 906 10.1038/nm.1967 19448633
2. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Mascola JR, Stiegler G, VanCott TC, et al. Nat Med 2000 6 207 210 10.1038/72318 10655111 (Pubitemid 30082367)
3. Distribution and three-dimensional structure of AIDS virus envelope spikes. Zhu P, Liu J, Bess J, et al. Nature 2006 441 847 852 10.1038/nature04817 16728975
4. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Montefiori DC, Mascola JR, Curr Opin HIV AIDS 2009 4 347 351 10.1097/COH.0b013e32832f4a4d 20048696
5. Toward an antibody-based HIV-1 vaccine. Hoxie JA, Annu Rev Med 2010 61 135 152 10.1146/annurev.med.60.042507.164323 19824826
6. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Crooks ET, Moore PL, Franti M, et al. Virology 2007 366 245 262 10.1016/j.virol.2007.04.033 17580087 (Pubitemid 47393683)
7. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. McBurney SP, Young KR, Ross TM, Virology 2007 358 334 346 10.1016/j.virol.2006.08.032 17011011 (Pubitemid 46138113)
8. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Quan FS, Sailaja G, Skountzou I, et al. Vaccine 2007 25 3841 3850 10.1016/j.vaccine.2007.01.107 17320250 (Pubitemid 46589751)
9. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM, J Virol 2005 79 7059 7067 10.1128/JVI.79.11.7059-7067.2005 15890945 (Pubitemid 40677337)
10. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, Spearman P, J Virol 2005 79 14804 14814 10.1128/JVI.79.23.14804-14814.2005 16282480 (Pubitemid 41636278)
11. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Bellier B, Huret C, Miyalou M, et al. Vaccine 2009 27 5772 5780 10.1016/j.vaccine.2009.07.059 19656495
12. Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. Mammano F, Salvatori F, Indraccolo S, De Rossi A, Chieco-Bianchi L, Göttlinger HG, J Virol 1997 71 3341 3345 9060707 (Pubitemid 27121580)
13. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Schnierle BS, Stitz J, Bosch V, et al. Proc Natl Acad Sci USA 1997 94 8640 8645 10.1073/pnas.94.16.8640 9238030 (Pubitemid 27335092)
14. A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Byland R, Vance PJ, Hoxie JA, Marsh M, Mol Biol Cell 2007 18 414 425 17108326 (Pubitemid 46213212)
15. Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Devitt G, Emerson V, Holtkotte D, Pfeiffer T, Pisch T, Bosch V, Virology 2007 361 465 471 10.1016/j.virol.2006.11.029 17208268 (Pubitemid 46584724)
16. Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. Kim YB, Lee MK, Han DP, Cho MW, AIDS Res Hum Retroviruses 2001 17 1715 1724 10.1089/08892220152741414 11788023 (Pubitemid 34114209)
17. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. Kalyanaraman VS, Rodriguez V, Veronese F, et al. AIDS Res Hum Retroviruses 1990 6 371 380 10.1089/aid.1990.6.371 2187500 (Pubitemid 20278797)
18. Plat-E: an efficient and stable system for transient packaging of retroviruses. Morita S, Kojima T, Kitamura T, Gene Ther 2000 7 1063 1066 10.1038/sj.gt.3301206 10871756 (Pubitemid 30398356)
19. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137 K). Tolstrup M, Selzer-Plön J, Laursen AL, et al. AIDS 2007 21 519 521 10.1097/QAD.0b013e3280187558 17301572
20. Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. Cantin R, Diou J, Bélanger D, Tremblay AM, Gilbert C, J Immunol Methods 2008 338 21 30 10.1016/j.jim.2008.07.007 18675270
21. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Center RJ, Wheatley AK, Campbell SM, et al. Vaccine 2009 27 6605 6612 10.1016/j.vaccine.2009.08.016 19712773
22. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Leclerc C, Dériaud E, Rojas M, Whalen RG, Cell Immunol 1997 179 97 106 10.1006/cimm.1997.1161 9268493 (Pubitemid 27400500)